GlassScriptPhysician profile
Luke A Iannuzzi
NPI 1598253635
$4,816.72
in general payments reported to CMS, 2019-2025
33 companies · $1,305 in 2025
The $1,305 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $290 · 2022: $538 · 2023: $1,275 · 2024: $1,410 · 2025: $1,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,989.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $927.83 | 2021-2025 | |
| Lilly USA, LLC | $813.59 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $690.64 | 2021-2025 | |
| Novo Nordisk INC | $511.30 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $273.35 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.18 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Phathom Pharmaceuticals, INC. | $215.99 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $109.68 | 2022-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Novartis Pharmaceuticals Corporation | $92.81 | 2021-2023 | |
| Dynavax Technologies Corporation | $92.48 | 2024 | Heplisav-B |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82.49 | 2024-2025 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $75.21 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $65.52 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.61 | 2024 | |
| Gilead Sciences, INC. | $57.69 | 2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $54.74 | 2024-2025 | |
| Dexcom, INC. | $51.35 | 2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $49.33 | 2021-2025 | Breztri, Farxiga |
| Amgen INC. | $47.33 | 2022 | |
| Xeris Pharmaceuticals, INC. | $46.12 | 2023 | Gvoke Hypopen |
| Ultragenyx Pharmaceutical INC. | $43.37 | 2023-2024 | Crysvita |
| Takeda Pharmaceuticals U.S.A., INC. | $33.65 | 2021-2023 | Trintellix |
| Exact Sciences Corporation | $32.80 | 2024 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $27.87 | 2022 | |
| Alnylam Pharmaceuticals INC. | $23.36 | 2025 | Givlaari |
| Abbott Laboratories | $21.11 | 2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $15.13 | 2025 | Auvelity |
| Almatica Pharma LLC | $14.94 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.80 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.37 | 2023 | Quviviq |
| Daiichi Sankyo INC. | $12.24 | 2022 | |
| Ibsa Pharma INC. | $11.75 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Iannuzzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.